Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical Products and Services company, has signed a distribution agreement with Amgen to supply part of its product portfolio to multiple countries across Africa and Asia.
Under the terms of the distribution agreement, Clinigen will provide physicians and pharmacists in certain territories with access to medicines which are not currently commercially available. Clinigen will act as the main point of contact for healthcare professionals wanting to access the medicines, managing all elements of the process including order and enquiry management, regulatory compliance, and logistics. The agreement will help support both companies’ missions of increasing access to medicines for patients across the world.
The following products are included in the agreement:
Sam Herbert, Chief Operating Officer, Clinigen, said:
“We are pleased to be partnering with Amgen to supply this portfolio of medicines for patients with unmet medical needs. This agreement will help to ensure healthcare professionals can obtain compliant access to critical medicines that are not commercially available in their country.”
Healthcare professionals can obtain details about the products by calling the Clinigen customer service team at +44 (0) 1932 824100 or emailing MedicineAccess@clinigengroup.com.
Patients seeking medical information should contact their physician.
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products platform focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.
Clinigen has more than 1,250 employees across five continents in 16 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 115 countries.
For more information on Clinigen, please visit http://www.clinigen.com
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information please contact: firstname.lastname@example.org
Melanie Toyne-SewellManaging Partner